Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Long-Term Capital Lease Obligation : HK$79 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Long-Term Capital Lease Obligation?

Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$79 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 (HK$99 Mil) to Mar. 2024 (HK$96 Mil) and declined from Mar. 2024 (HK$96 Mil) to Jun. 2024 (HK$79 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (HK$127 Mil) to Dec. 2022 (HK$124 Mil) and declined from Dec. 2022 (HK$124 Mil) to Dec. 2023 (HK$99 Mil).

Shenzhen Hepalink Pharmaceutical Group Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Long-Term Capital Lease Obligation Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

97.09

61.22

127.35

123.68

98.90

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															108.19	99.36	98.90	96.05	79.29

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Shenzhen Hepalink Pharmaceutical Group Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

002399:China

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.

Executives

Hong Ze Jun	2101 Beneficial owner
Orbimed Capital Llc	2102 Investment manager
Morgan Stanley & Co. International Plc	2105 Underwriter
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Avict Global Holdings Limited	2101 Beneficial owner
Worldwide Healthcare Trust Plc	2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co Headlines

No Headlines